for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Final phase 3 study data show Spinraza positive results

April 24 (Reuters) - Biogen Inc

* Final phase 3 study data show Spinraza(nusinersen) significantly improved motor function in children with later-onset spinal muscular atrophy

* Presymptomatic infants continued to achieve motor milestones generally consistent with normal development in new interim data analysis in study Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up